Does including machine learning predictions in ALS clinical trial analysis improve statistical power?

por Zhou, Nina, Manser, Paul
Publicado 2020

Cross‐sectional and longitudinal assessments of function in prodromal‐to‐mild Alzheimer's disease: A comparison of the ADCS‐ADL and A‐IADL‐Q scales

por Teng, Edmond, Li, Yihao, Manser, Paul T., Pickthorn, Karen, Butcher, Brandon D., Blendstrup, Mira, Randolph, Christopher, Sikkes, Sietske A.M.
Publicado 2023

Baseline [(18)F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease

por Teng, Edmond, Manser, Paul T., Sanabria Bohorquez, Sandra, Wildsmith, Kristin R., Pickthorn, Karen, Baker, Suzanne L., Ward, Michael, Kerchner, Geoffrey A., Weimer, Robby M.
Publicado 2021

Site-Specific Cerebrospinal Fluid Tau Hyperphosphorylation in Response to Alzheimer’s Disease Brain Pathology: Not All Tau Phospho-Sites are Hyperphosphorylated

por Barthélemy, Nicolas R., Toth, Balazs, Manser, Paul T., Sanabria-Bohórquez, Sandra, Teng, Edmond, Keeley, Michael, Bateman, Randall J., Weimer, Robby M., Wildsmith, Kristin R.
Publicado 2022

Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR‐SB

por Jamalian, Samira, Dolton, Michael, Chanu, Pascal, Ramakrishnan, Vidya, Franco, Yesenia, Wildsmith, Kristin, Manser, Paul, Teng, Edmond, Jin, Jin Y., Quartino, Angelica, Hsu, Joy C.
Publicado 2023

Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial

por Teng, Edmond, Manser, Paul T., Pickthorn, Karen, Brunstein, Flavia, Blendstrup, Mira, Sanabria Bohorquez, Sandra, Wildsmith, Kristin R., Toth, Bali, Dolton, Michael, Ramakrishnan, Vidya, Bobbala, Ashwini, Sikkes, Sietske A. M., Ward, Michael, Fuji, Reina N., Kerchner, Geoffrey A.
Publicado 2022